Druck Icon

Eckert & Ziegler winner of "Selected Landmarks in the Land of Ideas 2010"

Berlin, 24.11.2009. The Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist for isotope technology applications in medicine, science and industry has been awarded as a "Selected Landmark in the Land of Ideas 2010" as part of the contest "Germany - Land of Ideas". It is thus one of 365 selected innovative projects with which Germany will promote its being fit for the future and its richness in ideas in the coming year on one specific day respectively. More than 2,200 companies, municipal and private institutions, associations and unions nationwide applied to take part in this series of events under the patronage of Germany's federal president Horst Köhler. For the 20th anniversary of the German reunification 12 ideas that are related to the growing together of Germany have been awarded with a special award.

Eckert & Ziegler receives the special award for its innovative isotope technology with which it developed from a former GDR institute to one of the globally leading suppliers of isotope technology. The low-level radioactive components from Berlin-Buch are e.g. used in minimal invasive seed implantation against prostate cancer, a treatment that saves many men the chirurgical extraction of the prostate gland. Other areas of application for the radioactive components are the industrial measurement technology and imaging procedures in nuclear medicine. The awarding ceremony for the innovative isotope technology will take place on November 16th, 2010 at the Campus Berlin-Buch.

"Germany - Land of Ideas" is the joint business location initiative of the German government and the German industry, represented by the Federation of German Industry (Bundesverband der Deutschen Industrie, BDI). It is the aim of this initiative to convey at home and abroad an image of Germany as an innovative, cosmopolitan, and enthusiastic country.

Eckert & Ziegler AG focuses on advanced technologies in the field of radioisotopes and with its approx. 520 employees it is one of the largest producers of radioactive components for science, medicine and industry worldwide. The company, which is listed on the stock exchange, expects a turnover of 100 Mio. EUR and earnings per share of some 1.80 EUR in 2009.

The Board of Directors